Sarepta Therapeutics Inc. officials appeared unafraid of asking Center for Drug Evaluation and Research Director Janet Woodcock questions or even complaining about review division requests, while the US FDA was reviewing its application for the Duchenne Muscular Dystrophy Treatment Exondys 51 (eteplirsen).
Emails and other documents released Sept. 6 as part of a Freedom of Information Act request appear to...







